IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

Address

Ole Maaloes Vej 3

Website

https://www.iobiotech.com

Classification

Sector

Healthcare

Industry Group

Biotechnology

Industry

Biotechnology

Key Executives

Mr. David V. Smith, M.B.A.

Director

Mr. Jack Bech Nielsen

Director

Ms. Kathleen Sereda Glaub, M.B.A.

Director

Ms. Amy Sullivan, M.B.A.

CFO

Dr. Helen Collins, M.D.

Director

Dr. Peter Hirth, PhD

Chairman of the Board/Director

Ms. Heidi Hunter

Director

Dr. Mai-Britt Zocca, PhD

CEO/Director/Founder/President

Dr. Christian Elling, PhD

Director

Dr. Qasim Ahmad, M.D.

Chief Medical Officer

Mr. Muhammad Al-Hajj

Chief Scientific Officer

Mr. Devin Whittemore Smith

General Counsel

Ownership

Institution Holdings

Lundbeckfond Invest A/S

21,851,920 (33.169%)

Vivo Capital, LLC

6,173,439 (9.371%)

Novo A/S

5,747,067 (8.723%)

Novo Holdings A/S

5,747,067 (8.723%)

HBM Healthcare Investments Ltd

3,999,431 (6.071%)

HBM Partners Cayman Ltd

3,944,492 (5.987%)

Samsara BioCapital, LLC

3,640,015 (5.525%)

Samsara BioCapital, LP

3,640,015 (5.525%)

Morgan Stanley - Brokerage Accounts

2,281,682 (3.463%)

Marshall Wace Asset Management Ltd

2,105,262 (3.196%)

Individual Holdings

Ms. Amy Sullivan

74,382 (0.113%)

Dr. Mai-Britt Zocca, PhD

37,391 (0.057%)

Mr. Brian Burkavage

11,500 (0.018%)

Mr. Devin Whittemore Smith

4,938 (0.008%)

Details

Overview

Company Info

Key Ratios

Income

Balance Sheet

Cash Flow

Bubble

Make Smart Investment Choices